Login to Your Account



Earnings Roundup


Wednesday, May 9, 2012
• Dendreon Corp., of Seattle, reported a wider-than-expected loss for the first quarter, though revenues of $82 million for sales of prostate cancer vaccine Provenge (sipuleucel-T) fell in line with expecations. The net loss was $103.9 million, or 70 cents per share, compared to analyst estimates of a 63-cents-per-share loss. Dendreon said there was increased demand for Provenge, with 128 new infusion sites added in the first quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription